In this issue:
Biologic drug survival rates in the era of anti-IL-17 antibodies
TNF-α inhibitor-induced psoriasis
Certolizumab for psoriasis and PsA
Suboptimal response to adalimumab for hidradenitis suppurativa
Biopsychosocial effects of adalimumab for hidradenitis suppurativa
Dupilumab for atopic dermatitis in the elderly
Dupilumab for prurigo nodularis
Effectiveness of secukinumab and ustekinumab in psoriasis
Long-term response to guselkumab in psoriasis
Please login below to download this issue (PDF)